Phase 4 N=20 Randomized Single-blind Treatment

Reducing Suicidal Ideation Through Treatment of Nightmares-Post Traumatic Stress Disorder (PTSD)

Post Traumatic Stress Disorder · Suicidal Ideation · Nightmares

Bottom Line

View on ClinicalTrials.gov: NCT02199652 ↗

Enrolled (actual)

Serious AEs

10.0%

Results posted

Aug 2018

Primary outcome: Primary: Change Score for Scale for Suicide Ideation — 7.6; 8.2 units on a scale

Study Design & Population

Study type: Interventional
Phase: Phase 4
Interventions: Prazosin (Drug); Placebo (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Augusta University
Primary completion: Sep 2017

Outcome Measures

Outcome	Result	p-value
PRIMARY Change Score for Scale for Suicide Ideation	7.6; 8.2	—
SECONDARY Disturbing Dreams and Nightmare Severity Index	9.75; 15.8	—
SECONDARY Insomnia Severity Index	10.7; 15.4	—

Summary

Patients with PTSD, and frequent nightmares, and mild-moderate suicidal ideation, who are already taking a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI) will be randomized to either prazosin or placebo. The investigators hypothesize that patients receiving prazosin will have a greater reduction in suicidal ideation.

Eligibility Criteria

Inclusion Criteria

PTSD
Frequent nightmares
Suicidality

Exclusion Criteria

Schizophrenia
Bipolar
Substance abuse

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02199652). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.